Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of bone cancer
3.2.1.2 Growing awareness and early diagnosis
3.2.1.3 Advancements in medical technology and treatment modalities
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs
3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Primary bone cancer
5.2.1 Osteosarcoma
5.2.2 Chondrosarcoma
5.2.3 Ewing sarcoma
5.2.4 Other primary bone cancer
5.3 Secondary bone cancer
Chapter 6 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Targeted and immunotherapy
6.2.1 Denosumab
6.2.2 Imatinib
6.2.3 Sunitinib
6.2.4 Other targeted & immunotherapies
6.3 Chemotherapy
6.3.1 Doxorubicin
6.3.2 Cisplatin
6.3.3 Etoposide
6.3.4 Cyclophosphamide
6.3.5 Other chemotherapies
6.4 Radiation therapy
6.5 Surgery
Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Oncology centers & specialty clinics
7.4 Ambulatory surgical centers (ASCs)
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Advaxis Inc.
9.2 Amgen Inc.
9.3 Atlanthera
9.4 Baxter International Inc.
9.5 Bayer AG
9.6 Debiopharm
9.7 Eli Lilly and Company
9.8 Gradalis Inc.
9.9 Hikma Pharmaceutical PLC
9.10 Johnson & Johnson
9.11 Novartis AG
9.12 Pfizer Inc.
9.13 Recordati Group
9.14 Spectrum Pharmaceuticals Inc.
9.15 Takeda Pharmaceutical Company
